Introduction
Lung cancer is the leading cause of cancerrelated mortality for both men and women in the United States, and worldwide. In the United States, in 2010, there is estimated to be 222,520 new cases of lung cancer diagnosed and 157,300 deaths from the disease [Jemal et al. 2010] . Approximately 85% of primary lung cancers are categorized as non-small cell lung cancers (NSCLCs), which includes the main histologic subtypes of adenocarcinoma, squamous cell carcinoma, and large cell carcinoma [Ettinger et al. 2010] . Smoking remains the primary risk factor for the development of lung cancer; however, approximately 20% of cases of NSCLC occur in never (<100 cigarettes/life) or light smokers (<1015 pack-years) [Sun et al. 2007 ]. Stage IV, or metastatic, lung cancer is present in an approximately 40% of patients at the time of diagnosis and the 5-year estimated survival for patients with distant disease is dismal, at less than 4% [Azzoli et al. 2009 ].
The primary treatment of stage IV lung cancer is palliative with the use of systemic therapies [Ettinger et al. 2010; Azzoli et al. 2009] . A 2008 meta-analysis of 16 randomized controlled trials, involving 2714 patients, evaluated treatment with systemic chemotherapy versus best supportive care alone. A statistically significant improvement in overall survival (OS) with chemotherapy (hazard ratio [HR] 0.77) was reported [NSCLC Meta-Analysis Collaborative Group, 2008] . Current standard of care for first-line therapy of patients with stage IV NSCLC involves the use of a combination chemotherapy regimen, usually including either cisplatin or carboplatin plus another active agent [Azzoli et al. 2009] . Multiple randomized trials have failed to demonstrate superiority of any single combination regimen for the treatment of advanced NSCLC [Ettinger et al. 2010; Ohe et al. 2007; Scagliotti et al. 2002; Schiller et al. 2002] . The overall response rates (RRs) to the third-generation regimens used in these trials ranged from 19% to 32%, with median survivals of 814 months [Ettinger et al. 2010; Azzoli et al. 2009; Ohe et al. 2007; Scagliotti et al. 2002; Schiller et al. 2002] . Recent trials involving newer agents, have demonstrated varying responses to therapy based on tumor histology. A phase III trial demonstrated improved survival with the use of cisplatin/pemetrexed versus cisplatin/gemcitabine in patients with adenocarcinoma and large cell carcinoma, but not in patients with squamous histology [Scagliotti et al. 2008] . Bevacizumab, a recombinant humanized monoclonal antibody that binds to vascular endothelial growth factor (VEGF) and blocks the interaction between VEGF and the VEGF receptor, added to the combination of carboplatin and paclitaxel for the treatment of non-squamous advanced NSCLC has demonstrated increased RR (35 versus 15%), progression-free survival (PFS) (6.2 versus 4.5 months), and OS (12.3 versus 10.3 months) when compared with chemotherapy alone [Sandler et al. 2006] . Almost all patients eventually progress after initial treatment and require additional therapy. Three agents are approved by regulatory agencies for second-line therapy in advanced NSCLC: docetaxel [Shepherd et al. 2000] , pemetrexed (for non-squamous histology) [Hanna et al. 2004] and erlotinib [Shepherd et al. 2005 ]. All have been tested in randomized trials; however the RRs are below 10%, the PFSs below 23 months and very few unselected patients survive for longer than 9 months after starting secondline therapy. The early introduction of secondline agents as maintenance therapy, with either pemetrexed or erlotinib, immediately following a first-line platinum doublet, has demonstrated improved PFS compared with placebo [Cappuzzo et al. 2010; Ciuleanu et al. 2009] .
Despite the aforementioned recent advances with approval of more active chemotherapeutic and anti-angiogenesis agents for stage IV NSCLC, unselected patients derive only modest clinical benefits with significant toxicities from our standard therapies [Ettinger et al. 2010] . Therefore, interest in individualizing patient treatment to maximize clinical benefit has become a focus of clinical and scientific investigation. This concept has been termed 'personalized medicine' [Hamburg and Collins, 2010] , and it has become a reality for patients with NSCLC whose tumors harbor specific oncogene mutations. The current review will provide an update on the predictive role of epidermal growth factor receptor (EGFR) gene mutations, V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) gene mutations, and anaplastic lymphoma kinase (ALK) gene translocations in NSCLC. We focus on these three oncogenes, since they are the most clinically relevant molecular biomarkers, to date, in NSCLC. Other important molecular biomarkers that are predictive and prognostic in NSCLC have been reviewed elsewhere [Cheng et al. 2010] .
EGFR mutations in NSCLC and EGFR inhibitors EGFR is part of the HER/ErbB family of cellsurface receptor tyrosine kinases, which control the intracellular signal transduction pathways that regulate vital cellular functions, including proliferation, angiogenesis, and apoptosis [Sharma et al. 2007] . The receptors exist as monomers on the cell surface and homodimerize or heterodimerize in response to ligand, leading to autophosphorylation of the intracellular tyrosine kinase domain [Herbst et al. 2008] . This process then activates cell-signaling cascades involved in cell growth and survival [Nguyen et al. 2009; Sharma et al. 2007] . In malignant cells, including NSCLC cells, the activity of the receptor may become deregulated and no longer under the control of inherent inhibitory mechanisms. There are several ways in which EGFR can be altered, including mutation, amplification, and overexpression [Herbst et al. 2008] .
In 2004, the identification of somatic mutations in the EGFR gene provided the first glimpse of a clinically relevant NSCLC oncogene [Lynch et al. 2004; Paez et al. 2004; Pao et al. 2004 ]. There are several described mutations in the EGFR gene (Figure 1 ). The most common include an inframe deletion around the LREA motif (residues 746750) of exon 19 (4550% of mutations), and the L858R point mutation in exon 21 (4045% of mutations) [Sequist et al. 2007; Shigematsu et al. 2005; Tokumo et al. 2005] . EGFR mutations are more common in NSCLC from tumors with adenocarcinoma histology, and tumors in women, Asians, and never smokers [Sequist et al. 2007; Riely et al. 2006; Shigematsu et al. 2005] . Approximately 1015% of all NSCLCs in Caucasians and 20-30% of all NSCLCs in East-Asians harbor EGFR mutations, with the prevalence increasing to 50% or more in never smokers with NSCLC [Sequist et al. 2007; Riely et al. 2006; Shigematsu et al. 2005] . The mutations are seldom found in other epithelial malignancies EGFR mutations are oncogenic; they activate the EGFR-signaling pathway in the absence of ligand, and promote EGFR-mediated prosurvival and anti-apoptotic signals through downstream targets such as phosphatidylinositol-3-kinases (PI3K)/protein kinase B (AKT), extracellularsignal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) [Nguyen et al. 2009; Sharma et al. 2007] . These signaling networks make EGFR-mutated cells dependent on a functional EGFR for their survival [Sharma et al. 2007] , and hence they become 'addicted' to the receptor. Inhibition of EGFR leads to upregulation of pro-apoptotic molecules that activated the intrinsic mitochondrial apoptotic pathway and lead to cell death [Costa et al. 2007a; Cragg et al. 2007; Deng et al. 2007; Gong et al. 2007] . EGFR mutations also alter the tyrosine kinase pocket of the receptor to a degree that enhances the sensitivity to ATP-competitive EGFR inhibitors [Yun et al. 2007] .
Two oral EGFR tyrosine kinase inhibitors (TKIs) have reached regulatory approval for the treatment of NSCLC: gefitinib and erlotinib [Kim et al. 2008; Shepherd et al. 2005; Thatcher et al. 2005] . Gefitinib, at a dose of 250 mg or 500 mg daily, has a 1015% RR in patients previously treated with platinum-based regimens in phase II trials [Sequist et al. 2007; Kris et al. 2003] . Erlotinib, at a dose of 150 mg daily, has an objective RR of 10% in the second-line setting [Ciardiello and Tortora, 2008; Sequist et al. 2007; Perez-Soler et al. 2004] . Based on the results of these phase II trials, an international of tumors, and in the subgroup of the 261 patients who had a tumor with an EGFR mutation, a significantly longer PFS was attained with gefitinib versus carboplatinpaclitaxel (median 9.5 versus 6.3 months, HR 0.48; p < 0.001).
The RR was equally impressive at 71.2% for gefitinib in EGFR-mutated tumors (Table 2) . 
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Patients without an EGFR mutation, in contrast, had improved RR and PFS with chemotherapy rather than gefitinib [Mok et al. 2009 ].
In 2010, the first phase III trial of gefitinib versus chemotherapy based on selection of patients with known activating EGFR mutations was reported ( In all of the aforementioned trials, an OS advantage was not reported for gefitinib in comparison to chemotherapy (Table 2) . None of the trials were powered to detect differences in OS and there was extensive patient crossover to gefitinib therapy. It is likely the subsequent use of an EGFR TKI in EGFR-mutated tumors obscured major survival advantages [Maemondo et al. 2010; Mitsudomi et al. 2010; Mok et al. 2008] . RR, PFS and OS obtained with an EGFR TKI are similar independent of the line of therapy in which the TKI is provided [Rosell et al. 2009; Sequist et al. 2007] . The lack of OS advantage due to crossover effects will likely be an unavoidable fact in development of genotype-directed therapy in NSCLC. Therefore, use of PFS as a registration primary outcome will become more prevalent in the future development of TKIs for NSCLC. [Sequist et al. 2010] .
ALK translocations in NSCLC and ALK inhibitors
In 2007, a new fusion oncogene was identified in patients with NSCLC [Soda et al. 2007] . Approximately 27% of patients with NSCLC have tumors with an inversion in the short arm of chromosome 2 that results in the fusion of the echinoderm microtubule-associated protein-like 4 (EML4) gene with the ALK gene leading to the production of an EML4-ALK fusion tyrosine kinase [Solomon et al. 2009; Choi et al. 2008; Soda et al. 2007] , as indicated in Figure 1 . ALK is a transmembrane protein, which has a kinase domain and is not usually expressed in the lung [Soda et al. 2007 ]. EML4 and other less-frequent fusion partners, such as TFG and KIF5B, mediate ligand-independent dimerization, and therefore constitutive activity of the ALK tyrosine kinase domain [Takeuchi et al. 2009; Rikova et al. 2007] . In cell line and mouse models, EML4-ALK is highly oncogenic, activates the PI3K-AKT and MAPK-ERK pathways and induces lung tumors [Soda et al. , 2007 . Since many EML4-ALK variants have been described, a common nomenclature using the position of the breakpoints in the EML4 and ALK genes has been devised [Horn and [Shaw et al. 2009b; Koivunen et al. 2008] . In never or light smokers with NSCLC, the prevalence of ALK translocations may be as high as 2030% [Shaw et al. 2009b; Solomon et al. 2009 ].
The methods of detection of ALK translocations in NSCLC have not been well standardized. In the original reports, archival clinical specimens were tested using isolated RNA and reverse transcription polymerase chain reaction (RT-PCR) amplifications specific to ALK and its gene fusion partner [Takeuchi et al. 2009 Soda et al. 2007] . Immunohistochemical (IHC) detection of ALK epitopes with commercially available antibodies has been extremely difficult in lung cancers and has failed to confirm most cases positive by RT-PCR [Rodig et al. 2009; Takeuchi et al. 2009] . Another detection method for ALK translocations is fluorescence in situ hybridization (FISH). Break-apart probes can identify ALK translocations [Rodig et al. 2009; Shaw et al. 2009b; Takeuchi et al. 2009 Takeuchi et al. , 2008 , and a commercially available break-apart probe (Vysis LSI ALK Dual Color, Break Apart Rearrangement Probe, Abbott Molecular, Des Plaines, IL) has been used as the screening test to detect ALK-translocated NSCLC in the setting of clinical trials.
Specific ALK inhibitors have demonstrated activity against tumors with ALK translocations in preclinical studies [Settleman, 2009; Koivunen et al. 2008; McDermott et al. 2008; Christensen et al. 2007; Zou et al. 2007] . The most advanced small-molecule TKI targeting ALK translocations in NSCLC is called crizotinib (formerly PF02341066), which was developed as an inhibitor of MET but also functions as an inhibitor of ALK [Settleman, 2009; McDermott et al. 2008; Christensen et al. 2007] . Results from the initial phase I clinical trial of crizotinib and the expansion cohort of the recommended phase II dose for ALK translocated NSCLC were recently presented [Bang et al. 2010; Shaw et al. 2009a ] and subsequently published [Kwak et al. 2010] . Approximately 1500 NSCLCs were screened by the ALK break-apart FISH probe, and 82 patients were enrolled (Table 3) . Patients were treated with crizotinib 250 mg orally twice daily. The confirmed RR was 57%, with an additional 33% of patients meeting criteria for stable disease, including 6% who had unconfirmed partial responses [Bang et al. 2010; Kwak et al. 2010] . Median PFS has not yet been reached; however, with a median follow-up for PFS of 6.4 months; the probability of PFS at 6 months in this group is estimated at 72% [Bang et al. 2010; Kwak et al. 2010] . The most common reported toxicities included nausea/vomiting, diarrhea, mild visual disturbances, liver function test abnormalities, and peripheral edema [Bang et al. 2010; Kwak et al. 2010; Shaw et al. 2009a] .
Given these positive initial results, crizotinib has already entered phase II (PROFILE 1005, ClinicalTrials.gov identifier: NCT00932451) and III (PROFILE 1007, ClinicalTrials.gov identifier: NCT00932893) registration human studies for NSCLCs with ALK translocations. The randomized PROFILE 1007 clinical trial aims to confirm the superiority of crizotinib to standard single-agent second-line chemotherapy (pemetrexed or docetaxel) in ALK-translocated NSCLC. If the latter trial shows superiority of crizotinib, it is likely this agent and its companion diagnostic test will be approved by American and European regulatory agencies for use in ALKtranslocated NSCLC in the second-line setting. This would mark a new page of genotype-driven drug development for lung cancer.
KRAS mutations in NSCLC
Ras family (HRAS, NRAS, and KRAS) genes are frequently mutated in human cancers [Roberts et al. 2010] . In NSCLC, KRAS is one of the most commonly mutated oncogenes with single amino acid substitutions at residues G12 and G13 primarily identified (Figure 1 ) [Riely et al. 2009 ]. The frequency of KRAS mutations varies according to tumor histology (more frequent in adenocarcinomas than squamous cell carcinomas), patient ethnicity (more frequent in Caucasians than Asians) and smoking history (more frequent in smokers than never smokers) [Riely et al. 2009 . A meta-analysis of KRAS mutations in NSCLC described a frequency of 26% in tumors of current/former smokers, and 6% in tumors of never smokers [Mao et al. 2010] . Mutant KRAS renders the protein constitutively guanosine triphosphate (GTP) bound, which activates downstream effectors such as the MEK-ERK pathway and the PI3K-AKT pathway [Roberts et al. 2010] .
In NSCLC tumor specimens, KRAS mutations are usually mutually exclusive with EGFR mutations and ALK translocations [Riely et al. 2009; Shaw et al. 2009b] . The prognostic and predictive role of KRAS mutations in NSCLCs treated with EGFR inhibitors have been extensively reviewed elsewhere and is beyond the scope of the current review [Mao et al. 2010; Roberts et al. 2010; Riely et al. 2009] . Despite initial reports that KRAS-mutated NSCLC were intrinsically 'resistant' to the EGFR TKIs gefitinib and erlotinib due to lack of measurable radiographic responses [Pao et al. 2005b] , it is becoming clear that responses are seldom seen in any NSCLC that is EGFR wild type (WT), independent of their KRAS mutation status [Jackman et al. 2009 ]. This was highlighted in the IPASS trial, in which EGFR WT tumors had only a RR of 1.1% when patients were given gefitinib [Mok et al. 2009] . Therefore, it is likely that most EGFR WT NSCLCs, independent of KRAS and ALK status, display the same pattern of lack of significant radiographic responses to EGFR TKIs [Mao et al. 2010; Jackman et al. 2009; Shaw et al. 2009b] . In addition, most of the unselected phase III clinical trials of gefitinib and erlotinib did not disclose a negative predictive impact of KRAS in regards to PFS and OS [Mao et al. 2010; Roberts et al. 2010] . As an example, in the largest randomized trial of erlotinib versus placebo, BR.21, patients with mutant KRAS had a slightly nonsignificant trend to worsened survival compared with placebo (HR ¼ 1.67, p ¼ 0.31) [Zhu et al. 2008] [KhambataFord et al. 2010] . The current evidence does not support KRAS as an independent negative predictive marker for EGFR inhibitors in NSCLC [Mao et al. 2010] .
Conclusion
EGFR mutations have been consistently shown to be the most robust predictive biomarker for Therapeutic Advances in Medical Oncology 3 (3) radiographic response, symptom improvement and increment in PFS when EGFR TKIs are used for patients with advanced NSCLC. ALK translocations are predictive of major clinical and radiographic responses to ALK TKIs and studies are underway to provide evidence-based data of the clinical utility of this biomarker in NSCLC. These promising results for EGFR and ALK TKIs in selected molecular subgroups of NSCLC herald a new age of drug and clinical trial development for patients with NSCLC. Although only 15% of all NSCLCs have EGFR mutations and only 5% harbor ALK translocations, if one considers the disease burden of lung cancer as a whole, this translates into significant absolute number of patients that may derive benefits from EGFR and ALK TKIs. In the United States alone, approximately 30,000 cases of EGFR-mutated and 10,000 cases of ALK-translocated NSCLC will be diagnosed each year [Jemal et al. 2010] . These numbers exceed the total number of patients with a new diagnosis of Hodgkin's lymphoma, chronic myeloid leukemia, acute myeloid leukemia, and uterine cancer combined [Jemal et al. 2010] . Therefore, efforts to identify and treat even small subgroups of NSCLC will likely impact the morbidity and mortality attributed to this cancer.
Hefty efforts are being put in place for a detailed analysis of the mutational spectrum of 'drugable' oncogenes and tumor-suppressor genes in adenocarcinomas of the lung, such as the National Cancer Institute (NCI)-sponsored Lung Cancer Mutation Consortium (ClinicalTrials.gov identifier: NCT01014286). Outside EGFR, KRAS mutations and ALK translocations it has become clear that other oncogenes such as ErbB2, BRAF, PI3K, PDGFR, ROS, and MEK1 among others are also mutated, translocated or amplified in NSCLCs [Sharma et al. 2010] . It is foreseeable that in the near future most patients with NSCLC will have their specific therapy delineated by tumor genotyping. Despite this optimistic futurist look into individualized care of NSCLCs, the temptation of early adoption of the aforementioned molecular biomarkers will need to be tempered by rigorous evidencebased and cost-analysis research prior to widespread approval and implementation of tumor genotype into routine care of lung cancer. 
